TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30921297

Group type: EXPERIMENTAL
Intervention: Operative treatment with serious adverse events (SAEs)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Operative treatment without serious adverse events (SAEs)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Operative treatment (both with and without SAEs)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 286
Study: 27880946

Group type: EXPERIMENTAL
Intervention: DP001
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DP001 (previously treated with cinacalcet plus active vitamin D)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (previously treated with cinacalcet plus active vitamin D)
Number of subjects: 62
Study: 25766591

Group type: EXPERIMENTAL
Intervention: onabotulinum toxin (BoNTA) injected unilaterally in the corrugator muscle
Number of subjects: 5
Study: 22715124

Group type: EXPERIMENTAL
Intervention: Combined stress management and exercise (SMEX)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Stress management (SM)
Number of subjects: 286
Study: 20717045

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aspirin enteric-coated 81 mg once daily
Number of subjects: 45
Study: 18930599

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (Genotropin; Pfizer) for 6 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Baseline conditions (GH deficient females with Sheehan's syndrome)
Number of subjects: 22
Study: 17084630

Group type: EXPERIMENTAL
Intervention: Orthopedic corset
Number of subjects: 11

Group type: COMPARATOR
Intervention: No corset (control)
Number of subjects: 11
Study: 15197122

Group type: EXPERIMENTAL
Intervention: Epidural continual intermittent boluses (CIB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 42
Study: 11339777

Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) cisatracurium at the adducting laryngeal muscles
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) cisatracurium at the diaphragm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional monitoring site (adductor pollicis muscle)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Novel paravertebral site
Number of subjects: 24
Study: 9039832

Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring) in anemic children
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (continuation of coffee) in nonanemic children
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (continuation of coffee) in anemic children
Number of subjects: 139
Study: 8179147

Group type: EXPERIMENTAL
Intervention: Positive intra-operative suggestions
Number of subjects: 60
Study: 2465747

Group type: EXPERIMENTAL
Intervention: Regimen I: Intravenous cisplatin (100-150 mg/m2 on day 1), intramuscular bleomycetin (10 mg on days 2-4), intravenous 5-fluorouracil (400 mg/m2 on days 2-4)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Regimen II: Intramuscular bleomycetin (10 mg on days 1-3), intravenous 5-fluorouracil (400 mg/m2 on days 1-3), intravenous cisplatin (100-150 mg/m2 on day 4)
Number of subjects: 22
Study: 30106529

Group type: EXPERIMENTAL
Intervention: Two-step oral hygiene sequence: 0.454% stannous fluoride dentifrice followed by 3.0% hydrogen peroxide whitening gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate oral rinse and 0.76% sodium monofluorophosphate dentifrice
Number of subjects: 44
Study: 27278933

Group type: EXPERIMENTAL
Intervention: JADE with nurse-coordinated follow-up visits
Number of subjects: 3586

Group type: COMPARATOR
Intervention: DIAMOND
Number of subjects: 3586
Study: 26637482

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii multiglycosides (TWG) combined with prednisone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tacrolimus (TAC) combined with prednisone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TWG
Number of subjects: 53

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 53
Study: 23216100

Group type: EXPERIMENTAL
Intervention: Topical epidural of preservative‐free morphine and dexmedetomidine administered via gel foam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent hydromorphone postoperatively
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both forms of analgesia (topical epidural and hydromorphone)
Number of subjects: 30
Study: 21967492

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study: 18463550

Group type: EXPERIMENTAL
Intervention: Gait speed measurement in patients requiring physical assistance to walk (n=13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gait speed measurement in patients who can walk without physical assistance (n=22)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gait speed measurement for all subjects combined (n=35)
Number of subjects: 35
Study: 16540840

Group type: EXPERIMENTAL
Intervention: Caffeinated drink (5 mg x kg(‐1))
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12959740

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 18
Study: 10719310

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Specific IgE determination for hazelnut (positive CAP response >/=0.7 kU/L)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Skin tests with commercial hazelnut extract
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Skin tests with natural food
Number of subjects: 86
Study: 9202559

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 1527539

Group type: EXPERIMENTAL
Intervention: Epanutin capsules
Number of subjects: 17

Group type: COMPARATOR
Intervention: Phenytoin BP tablets (Regent Laboratories)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Epanutin Infatabs
Number of subjects: 17

Group type: COMPARATOR
Intervention: Generic 100 mg tablets
Number of subjects: 17
Study: 3893025

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% plain
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% with epinephrine
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plain
Number of subjects: 1048
Study: 31066987

Group type: EXPERIMENTAL
Intervention: E-cigarettes (0, 18, or 36 mg/ml nicotine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Own cigarettes
Number of subjects: 15
Study: 30304141

Group type: EXPERIMENTAL
Intervention: Mecobalamin (500 µg three times a day)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 224
Study: 27382813

Group type: EXPERIMENTAL
Intervention: 0.1 mg.kg‐1 oxycodone intravenously 10 min prior to the operation for 2 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline intravenously
Number of subjects: 60
Study: 24215554

Group type: EXPERIMENTAL
Intervention: Hand exercises and a soft prefabricated thumb orthosis
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hand exercises only (control group)
Number of subjects: 59
Study: 22309404

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) with stimulation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: sVA (VA with stimulation)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: nsVA (VA without stimulation)
Number of subjects: 65
Study: 20056782

Group type: EXPERIMENTAL
Intervention: Structured functional assessments by GPs
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual assessment of functional ability by GPs
Number of subjects: 57
Study: 18076539

Group type: EXPERIMENTAL
Intervention: Ziprasidone monotherapy (57.3 +/- 33.9 mg/day)
Number of subjects: 21
Study: 16251309

Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg/day (100 mg initial dose, then 50 mg intravenously twice daily)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously twice daily)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg/day
Number of subjects: 546

Group type: COMPARATOR
Intervention: Combination of vancomycin and aztreonam
Number of subjects: 546
Study: 11867387

Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg administered randomly and blindly before cooling)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg administered IV after 10 min of shivering)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Urapidil (during shivering)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (administered randomly and blindly before cooling)
Number of subjects: 7
Study: 10597551

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suxamethonium 2 mg.kg‐1
Number of subjects: 40
Study: 8531933

Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Terbinafine treatment course 4
Number of subjects: 60
Study: 2386275

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 65
Study: 7358867

Group type: EXPERIMENTAL
Intervention: Nefopam (Acupan)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (Benadryl)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Parenteral Nefopam
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Oral Nefopam
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 196
Study: 29743105

Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Good School Toolkit exposure
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Implementation of a 'low' number of program school‐led activities
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Teacher Toolkit exposure
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Individual factors associated with Toolkit exposure
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Post-intervention risk factors
Number of subjects: 1921
Study: 28034969

Group type: EXPERIMENTAL
Intervention: New learning tool for needle insertion accuracy skills (using two video cameras, a monitor, and an ultrasound machine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional practice methods (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: New learning tool for inexperienced participants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional practice methods for experienced participants
Number of subjects: 30
Study: 26178495

Group type: EXPERIMENTAL
Intervention: Ulinastatin plus octreotide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 120
Study: 22706167

Group type: EXPERIMENTAL
Intervention: Probiotic drink (daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54
Study: 21925126

Group type: EXPERIMENTAL
Intervention: BI 207127 400 mg 3 times daily plus 120 mg BI 201335 once daily and 1000 to 1200 mg/day ribavirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BI 207127 600 mg 3 times daily plus 120 mg BI 201335 once daily and 1000 to 1200 mg/day ribavirin
Number of subjects: 32
Study: 17581594

Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 16969289

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 12037783

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1,000 mg followed by a 6-day taper from 200 to 20 mg/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1,000 mg for three consecutive days
Number of subjects: 38
Study: 9648325

Group type: EXPERIMENTAL
Intervention: Live Zebra Tarantula placed next to the stimulus light by the door (threat and safety/escape coincide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live Zebra Tarantula placed next to the stimulus light by the wall (threat and safety/escape divided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition (control group)
Number of subjects: 0
Study: 7866361

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 0
Study: 2760497

Group type: EXPERIMENTAL
Intervention: Gastric microbial colonization
Number of subjects: 40
Study: 4564764

Group type: EXPERIMENTAL
Intervention: Orudis
Number of subjects: 88

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 88
Study: 7351677

Group type: EXPERIMENTAL
Intervention: Supplemental albumin infusion (31 gm during operation followed by 150 gm/day for 5 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No albumin (control group)
Number of subjects: 94
Study: 29953340

Group type: COMPARATOR
Intervention: Bleaching with 40% hydrogen peroxide gel (Opalescence Boost, Ultradent)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bleaching + application of calcium silicate/phosphate gel (Regenerate Serum, Unilever - Rs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bleaching + 2% sodium fluoride gel
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bleaching + remineralizing gel (Regenerate Serum)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Brushed with Regenerate toothpaste
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Brushed with Close Up toothpaste
Number of subjects: 240
Study: 26403322

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Oral antipsychotics (APs)
Number of subjects: 442
Study: 27932196

Group type: EXPERIMENTAL
Intervention: mVLT using 2.5-mLkg-1 boluses of Ringer's acetate
Number of subjects: 0
Study: 24907853

Group type: EXPERIMENTAL
Intervention: Microbial skin sealant
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bare skin
Number of subjects: 140
Study: 22682671

Group type: EXPERIMENTAL
Intervention: Usual care plus exercise intervention delivered over 6 months
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 208
Study: 19579605

Group type: COMPARATOR
Intervention: 5-day terlipressin treatment (Group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10-day terlipressin treatment (Group B)
Number of subjects: 25
Study: 17805339

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO), administered for > or = 24 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo, administered for > or = 24 days
Number of subjects: 71
Study: 14985664

Group type: COMPARATOR
Intervention: Sterile gloves
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Clean nonsterile gloves
Number of subjects: 816
Study: 11890385

Group type: EXPERIMENTAL
Intervention: Standardized, 30‐minute Reiki session
Number of subjects: 23
Study: 9445498

Group type: COMPARATOR
Intervention: Nucleotide formula
Number of subjects: 311

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 311
Study: 8522777

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 150
Study: 2236712

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 2 ml (0.75%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 3 ml (0.5%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 6 ml (0.25%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 9 ml (0.166%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg in 3 ml (0.25%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 15 mg in 3 ml (0.5%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 22.5 mg in 3 ml (0.75%)
Number of subjects: 120
Study: 282482

Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31132978

Group type: EXPERIMENTAL
Intervention: 5mg melatonin plus regular treatments
Number of subjects: 41

Group type: COMPARATOR
Intervention: Regular treatments only
Number of subjects: 41
Study: 28806487

Group type: EXPERIMENTAL
Intervention: Ma-Pi 2 diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 12
Study: 25547503

Group type: EXPERIMENTAL
Intervention: sorafenib plus erlotinib
Number of subjects: 720

Group type: COMPARATOR
Intervention: sorafenib plus placebo
Number of subjects: 720
Study: 24132249

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 21341394

Group type: COMPARATOR
Intervention: PSI = 5
Number of subjects: 278

Group type: COMPARATOR
Intervention: CURB-65 ≥ 3
Number of subjects: 278

Group type: COMPARATOR
Intervention: APACHE II ≥ 25
Number of subjects: 278
Study: 19057451

Group type: EXPERIMENTAL
Intervention: US guidance
Number of subjects: 152

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 152
Study: 17873254

Group type: EXPERIMENTAL
Intervention: Decision aid-supported patient choice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician-supported choice of either intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision aid-supported choice of either intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical care (control)
Number of subjects: 0
Study: 15312228

Group type: EXPERIMENTAL
Intervention: Remifentanil (initial rate 9 microg kg(‐1) h(‐1), titrated before adding propofol [0.5 mg kg(‐1) h(‐1)] during days 1-3, midazolam [0.03 mg kg(‐1) h(‐1)] during days 4 and 5)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 121

Group type: COMPARATOR
Intervention: Hypnotic-based regimen (fentanyl or morphine with propofol and midazolam)
Number of subjects: 121
Study: 11597377

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional mouthwash
Number of subjects: 35
Study: 9816659

Group type: EXPERIMENTAL
Intervention: Repair with PDS II-cord augmentation (G1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acute BTB ligament replacement (G2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late BTB ligament replacement (G3)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late BTB ligament replacement with PDS II-cord augmentation (G4)
Number of subjects: 200
Study: 7912875

Group type: EXPERIMENTAL
Intervention: Melperon (15-30 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (4-10 mg)
Number of subjects: 100
Study: 2731086

Group type: EXPERIMENTAL
Intervention: Flunarizine (15 mg daily)
Number of subjects: 25
Study: 1140623

Group type: EXPERIMENTAL
Intervention: Intravenous metiamide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 30461621

Group type: EXPERIMENTAL
Intervention: Tonsillectomy by low-temperature plasma
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tonsil-pecking (Control)
Number of subjects: 72
Study: 28404647

Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Chest Tube Drainage (CTD)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA) in SSP subgroup
Number of subjects: 127

Group type: COMPARATOR
Intervention: Chest Tube Drainage (CTD) in SSP subgroup
Number of subjects: 127
Study: 26080850

Group type: EXPERIMENTAL
Intervention: Glutamine (20 g/d), EPA (3.3 g/d), branched-chain amino acids (8 g/d)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (dietary counseling and routine nutritional supports only)
Number of subjects: 104
Study: 23010883

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 36 months
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 7808
Study: 20583512

Group type: EXPERIMENTAL
Intervention: Nintendo Wii with Marble Mania (experimental group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no game play)
Number of subjects: 21
Study: 21158148

Group type: EXPERIMENTAL
Intervention: HBO pretreatment twice (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HBO pretreatment 5 times (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBO pretreatment once per day for 2 days (HBO group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison group (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBO pretreatment once per day for 3 days (HBO group)
Number of subjects: 20
Study: 15858959

Group type: EXPERIMENTAL
Intervention: S. boulardii (250 mg daily for 5 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12529661

Group type: EXPERIMENTAL
Intervention: G-CSF mobilization
Number of subjects: 342
Study: 10476018

Group type: EXPERIMENTAL
Intervention: Students taught by Patient Partners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Students taught by Consultants
Number of subjects: 0